7.28k followers • 31 symbols Watchlist by Yahoo Finance
Follow this list to discover and track large drug and biotechnology companies.
Curated by Yahoo Finance
Follow this list to discover and track large drug and biotechnology companies. These companies develop speciality drugs and treatments for various diseases and medical conditions. Although there are risks associated with the success of the drug, those that succeed tend to have a strong series of earnings growth over a period of time, especially when they are backed by patents.
The list includes stocks priced at $5 or more with a three-month average daily trading volume in excess of 200,000 shares. This list is generated daily and sorted by market cap; the gains are based on the latest closing price and limited to the top 30 stocks that meet the criteria.
This watchlist is similar to a discontinued watchlist called ‘Battling Cancer’.
Yahoo Finance employs sophisticated algorithms to monitor and detect trends in the global financial markets. We bring these insights to you in the form of watchlists.
Find other winning investment ideas with the Yahoo Finance Screener.How are these weighted?
The stocks in this watchlist are weighted equally.
|Watchlist||Change today||1-month return||1-year return||Total return|
|Biotech and drug stocks||-0.22%||-||-||-|
|Symbol||Company name||Last price||Change||% change||Market time||Volume||Avg vol (3-month)||Market cap|
|LLY||Eli Lilly and Company||598.05||+9.78||+1.66%||4:00 pm GMT-5||2.44M||3.23M||567.73B|
|NVO||Novo Nordisk A/S||96.64||-0.17||-0.18%||4:00 pm GMT-5||2.97M||4.77M||431.00B|
|JNJ||Johnson & Johnson||154.42||-0.98||-0.63%||4:00 pm GMT-5||6.15M||6.77M||371.73B|
|ABBV||AbbVie Inc.||149.28||+1.31||+0.89%||4:00 pm GMT-5||5.57M||4.94M||263.56B|
|MRK||Merck & Co., Inc.||103.75||-0.13||-0.13%||4:00 pm GMT-5||7.45M||7.31M||262.90B|
|RHHBY||Roche Holding AG||36||+0.42||+1.18%||3:59 pm GMT-5||1.83M||2.10M||233.32B|
|NVS||Novartis AG||96.3||+0.37||+0.39%||4:00 pm GMT-5||3.26M||1.56M||198.88B|
|AZN||AstraZeneca PLC||63.25||-0.26||-0.41%||4:00 pm GMT-5||4.55M||5.54M||196.52B|
|PFE||Pfizer Inc.||28.78||+0.15||+0.52%||4:00 pm GMT-5||31.26M||31.40M||162.50B|
|AMGN||Amgen Inc.||269.12||-2.19||-0.81%||4:00 pm GMT-5||2.50M||2.46M||144.03B|
|SNY||Sanofi||46.32||+0.26||+0.56%||4:00 pm GMT-5||1.33M||2.08M||116.16B|
|BMY||Bristol-Myers Squibb Company||50.31||+0.15||+0.30%||4:00 pm GMT-5||10.11M||13.23M||102.37B|
|GILD||Gilead Sciences, Inc.||79.02||+0.97||+1.24%||4:00 pm GMT-5||6.20M||5.80M||98.46B|
|REGN||Regeneron Pharmaceuticals, Inc.||840.14||-9.04||-1.06%||4:00 pm GMT-5||359.16k||455.30k||91.53B|
|VRTX||Vertex Pharmaceuticals Incorporated||350.15||-3.80||-1.07%||4:00 pm GMT-5||1.39M||1.21M||90.23B|
|ZTS||Zoetis Inc.||184.6||+2.77||+1.52%||4:00 pm GMT-5||1.47M||1.84M||84.75B|
|GSK||GSK plc||35.94||-0.06||-0.17%||4:00 pm GMT-5||1.50M||3.56M||74.02B|
|TAK||Takeda Pharmaceutical Company Limited||14.06||-0.02||-0.14%||4:00 pm GMT-5||837.86k||1.87M||44.12B|
|SGEN||Seagen Inc.||218.98||+0.65||+0.30%||4:00 pm GMT-5||1.14M||1.38M||41.31B|
|HLN||Haleon plc||8.19||-0.03||-0.36%||4:00 pm GMT-5||2.95M||5.37M||37.82B|
|BIIB||Biogen Inc.||239.29||+0.17||+0.07%||4:00 pm GMT-5||929.36k||981.14k||34.67B|
|BAYRY||Bayer Aktiengesellschaft||8.54||+0.01||+0.12%||3:59 pm GMT-5||1.25M||1.39M||33.67B|
|MRNA||Moderna, Inc.||80.32||+0.37||+0.46%||4:00 pm GMT-5||2.75M||4.13M||30.62B|
|ARGX||argenx SE||453.48||-4.29||-0.94%||4:00 pm GMT-5||142.28k||259.38k||27.00B|
|BNTX||BioNTech SE||103.43||+1.50||+1.48%||4:00 pm GMT-5||452.62k||659.37k||24.80B|
|ALPMY||Astellas Pharma Inc.||11.958||-0.30||-2.46%||3:55 pm GMT-5||213.06k||290.26k||21.73B|
|ALNY||Alnylam Pharmaceuticals, Inc.||170.04||-7.22||-4.07%||4:00 pm GMT-5||467.36k||671.50k||21.34B|
|GMAB||Genmab A/S||32.28||-0.08||-0.25%||4:00 pm GMT-5||299.29k||839.88k||21.09B|
|BGNE||BeiGene, Ltd.||175||-4.36||-2.43%||4:00 pm GMT-5||238.53k||212.51k||19.53B|
|BMRN||BioMarin Pharmaceutical Inc.||92.94||-2.00||-2.11%||4:00 pm GMT-5||1.78M||1.72M||17.66B|
The FDA approved gene-editing therapy Casgevy to treat sickle cell disease. Developed by Vertex Pharmaceuticals (VRTX) and CRISPR Therapeutics (CRSP), the one-time treatment harnesses gene editing advancements. Vertex CEO Dr. Reshma Kewalramani says the approach involves extracting a patient's stem cells, correcting the defect in those cells using CRISPR gene editing tools, then re-infusing the edited cells into the patient - relieving painful symptoms. Patients who undergo this $2.2 million procedure may eliminate painful sickle cell crises called VOC's. Kewalramani contrasts the cost against the $4-6 million lifetime price tag for conventional sickle cell management. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.
In the latest trading session, Gilead Sciences (GILD) closed at $79.02, marking a +1.24% move from the previous day.
Bristol Myers Squibb (BMY) closed at $50.31 in the latest trading session, marking a +0.3% move from the prior day.